Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Revvity ( (RVTY) ) has shared an announcement.
On January 12, 2026, Revvity said it will report its fourth-quarter and full-year 2025 results before the market opens on February 2, 2026, followed by an earnings call led by CEO Prahlad Singh and CFO Max Krakowiak, and confirmed that Singh is scheduled to present at the J.P. Morgan Healthcare Conference on January 13, 2026. The company issued preliminary figures indicating fourth-quarter 2025 reported and organic revenue growth of about 6% and 4%, respectively, implying roughly $772 million in sales, and full-year 2025 reported and organic revenue growth of about 4% and 3%, respectively, for approximately $2.855 billion in revenue, while also indicating that adjusted earnings per share for 2025 are now expected to come in above the previously guided upper end of $5.00, signaling operational outperformance and a stronger earnings profile heading into 2026.
The most recent analyst rating on (RVTY) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Revvity stock, see the RVTY Stock Forecast page.
Spark’s Take on RVTY Stock
According to Spark, TipRanks’ AI Analyst, RVTY is a Neutral.
Revvity’s overall stock score reflects strong technical momentum and strategic growth initiatives, tempered by high valuation concerns and mixed financial performance. The company’s ability to sustain growth while addressing profitability and cash flow challenges will be crucial.
To see Spark’s full report on RVTY stock, click here.
More about Revvity
Revvity, Inc., a member of the S&P 500 index, provides health science solutions, technologies, expertise and services spanning complete workflows from discovery to development and from diagnosis to cure, with specialized focus in translational multi-omics, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With 2024 revenue of more than $2.7 billion and about 11,000 employees, the company serves pharmaceutical and biotech customers, diagnostic laboratories, academia and governments in more than 160 countries.
Average Trading Volume: 1,386,608
Technical Sentiment Signal: Buy
Current Market Cap: $11.84B
For an in-depth examination of RVTY stock, go to TipRanks’ Overview page.